Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, ...

Cases of the highly infectious bacteria Clostridioides difficile, or C. diff, which has killed thousands have soared to a 12 year high.

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin ...

The pathogen C. diff — the most common cause of health care-associated infectious diarrhea — can use a compound that kills the human gut’s resident microbes to survive and grow ...

(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile ...

Factors linked to C difficile infection in patients with IBD include IBD activity prior to infection, shorter disease duration, previous use of corticosteroids, and prior hospitalisation.

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year.

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk ...

Opinion: The FDA must act so patients with refractory C. difficile infection can access lifesaving fecal transplants.

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind ...